Linezolid Tablet
Product Images NDC 64980-561

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Linezolid (NDC 64980-561). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Linezolid-graph01 (Linezolid Graph01)

LINEZOLID PLASMA CONC, pg/mL This text appears to be a graph or chart showing Linezolid plasma concentrations in picograms per milliliter (pg/mL) over time. The x-axis represents the time after dose in hours, while the y-axis represents the concentration of Linezolid in the plasma. The graph shows data points at 0, 2, 4, 6, 8, 10, and 12 hours after a dose of 600 mg oral Linezolid every 12 hours. The concentration values are not available as they were not included or are not readable in the provided text.*

FDA Label Image

Linezolid-label01 (Linezolid Label01)

FDA Label Image

Linezolid-struct (Linezolid Struct)

FDA Label Image

Linezolid-table (Linezolid Table)

FDA Label Image

Linezolid-table02 (Linezolid Table02)

Not available.*

FDA Label Image

Linezolid-table03 (Linezolid Table03)

This text provides information on the adverse reactions observed in patients receiving Linezolid, Cefadroxil, and Vancomycin for various indications. The data includes the reported incidence of different symptoms such as diarrhea, vomiting, headache, anemia, thrombocytopenia, nausea, abdominal pain, loose stools, eosinophilia, pruritus, and vertigo. The text also mentions the dosage regimen for different age groups receiving Linezolid or Cefadroxil orally or intravenously, and vancomycin intravenously.*

FDA Label Image

Linezolid-table06 (Linezolid Table06)

Laboratory Assay for Uncomplicated Skin and Skin Structure Infections includes the evaluation of various parameters such as Hemoglobin (g/dL), Platelet count (x 10/mm?), WBC (x 10/mm?), and Neutrophils (x 10/mm?), using Linezolid, Cefadroxil, Linezolid, and Vancomycin drugs. The results provided in the text are the values obtained for these parameters. Additionally, the text also mentions the dosages of Linezolid and Cefadroxil for patients of different age groups, as well as the dosages of Linezolid and Vancomycin for patients from birth through 11 years of age.*

FDA Label Image

Linezolid-table07 (Linezolid Table07)

FDA Label Image

Linezolid-table08 (Linezolid Table08)

FDA Label Image

Linezolid-table09 (Linezolid Table09)

FDA Label Image

Linezolid-table10 (Linezolid Table10)

FDA Label Image

Linezolid-table11 (Linezolid Table11)

This text provides pharmacokinetic data for linezolid, a medication used to treat certain infections. The text includes information on the exposure (measured by AUC, or area under the curve) and elimination half-life (measured by t) of linezolid and its two major metabolites (metabolite A and metabolite B) in subjects with end-stage renal disease (ESRD). The AUC values are given in mcg h/mL, and the t values are given in hours. Linezolid has an AUC of 181 mcg h/mL and a t of 8.3 hours. Metabolite A has an AUC of 153 mcg h/mL and a t of 15.9 hours. Metabolite B has an AUC of 356 mcg h/mL and a t of 34.8 hours. The text also mentions that metabolite B is the major metabolite of linezolid. It is worth noting that all these values were measured between hemodialysis sessions in ESRD subjects.*

FDA Label Image

Linezolid-table13 (Linezolid Table13)

This text provides information on the effectiveness of different antibiotics in curing certain pathogens. It shows the number and percentage of cases that were cured using Linezolid and Vancomycin for different types of bacteria, such as Staphylococcus aureus (both Methicillin-resistant and non-resistant strains) and Streptococcus pneumoniae. However, there is no information available regarding the context or specific conditions of the evaluation.*

FDA Label Image

Linezolid-table14 (Linezolid Table14)

This text provides information on the effectiveness of different drugs in curing certain pathogens. The pathogens listed include Staphylococcus aureus, Methicillin-resistant S. aureus, Streptococcus agalactiae, and Streptococcus pyogenes. The success rates of curing these pathogens with the drugs Linezolid and Oxacillin/Dicloxacillin are also given as percentages. For example, Linezolid cured 88% of Staphylococcus aureus cases and 67% of Methicillin-resistant S. aureus cases.*

FDA Label Image

Linezolid-table15 (Linezolid Table15)

This text provides information on the effectiveness of the drug Linezolid compared to a comparator in curing different pathogens. The table shows the percentage of cases cured for each pathogen, including Staphylococcus aureus, Methicillin-resistant S. aureus, and Streptococcus agalactiae. The numbers indicate the number of cases cured out of the total number of cases evaluated.*

FDA Label Image

Linezolid-table16 (Linezolid Table16)

Not available*

FDA Label Image

Linezolid-table17 (Linezolid Table17)

FDA Label Image

Linezolidtable04 (Linezolidtable04)

FDA Label Image

Linezolidtable05 (Linezolidtable05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.